Optiver Holding’s Intellia Therapeutics NTLA Stock Holding History

Optiver Holding’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-516	Closed	-$8.91K	–	2813
2025 Q3	$8.91K	Buy	+516	New	+$6.36K	﹤0.01%	1366

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Optiver Holding's NTLA Position: Q4 2025 in Review

Optiver Holding sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 516 shares — an estimated $8.91K sold.

Optiver Holding first reported a position in NTLA in Q3 2025 and held it in 1 quarter. The position peaked at $8.91K in Q3 2025. 291 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

Optiver Holding reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
Optiver Holding sold 516 Intellia Therapeutics shares in Q4 2025, an estimated $8.91K.
Optiver Holding first reported a position in Intellia Therapeutics in Q3 2025 and held it in 1 quarter.
Optiver Holding's Intellia Therapeutics position peaked at $8.91K in Q3 2025.
291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Optiver Holding's 13F filing for Q4 2025, filed 17 Feb 2026.